Overview

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Status:
Terminated

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, efficacy, and pharmacokinetics in a carefully monitored cohort of pediatric subjects infected with hepatitis C virus (HCV) on a telaprevir-based regimen in Part A and with dose adjustments if needed before Part B.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Vertex Pharmaceuticals Incorporated

Collaborator:

Janssen Pharmaceuticals

Treatments:

Interferon-alpha
Peginterferon alfa-2b
Ribavirin